Boston Scientific (NYSE:BSX) said it won CE Mark approval in the European Union for its Rhythmia 3D heart mapping device, spurring investors to send its stock to another 52-week high today.
The Natick, Mass.-based medical device company said EU regulators OK’d the Rhythmia device for cardiac catheter ablations and other electrophysiology procedures.
The news sent BSX shares to an $8.59 peak today, its highest point in the last year. Shares were trading at $8.55 as of about 10:30 a.m. today, up 3.0% from yesterday’s close. The stock had logged a prior high of $8,25 per share earlier this week after Boston Scientific revealed data showing that its Watchman device is superior to the anticoagulant drug Warfarin.
Boston Scientific acquired the Rhythmia mapping device along with Rhythmia Medical for $295 million last year.
"We believe the Rhythmia mapping system can become a leader in EP mapping with unparalleled speed, clarity and simplicity which should enable electrophysiologists to perform procedures with great efficiency and precision," electrophysiology general manager Pete Sommerness said in prepared remarks. "Bringing the Rhythmia system to our electrophysiology customers is a major step toward realizing our vision to redefine ablation technology."
